Douglas Bell

Douglas Bell

Auto-generated profile, based on publicly available information

Douglas Bell

Department of Cardiac Surgery, Queensland Children's Hospital, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
LFLaura S. Fong
Laura S. Fong
KBKim Betts
Kim Betts
DBDouglas Bell
Douglas Bell
IKIgor E. Konstantinov
Igor E. Konstantinov
INIan A. Nicholson
Ian A. Nicholson
DADavid Andrews
David Andrews

1 January 2021 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PNPhillip S. Naimo
Phillip S. Naimo
DBDouglas Bell
Douglas Bell
TFTyson A. Fricke
Tyson A. Fricke
YDYves D'UDekem
Yves D'UDekem
CBChristian P. Brizard
Christian P. Brizard
IKIgor E. Konstantinov
Igor E. Konstantinov

31 January 2019 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
MYMatthew S Yong
Matthew S Yong
MZMichael Z L Zhu
Michael Z L Zhu
DBDouglas Bell
Douglas Bell
NANelson Alphonso
Nelson Alphonso
JBJohann Brink
Johann Brink
IKIgor E Konstantinov
Igor E Konstantinov
OBJECTIVES: Pulmonary artery (PA) sling is a rare vascular anomaly often associated with congenital tracheal stenosis. We describe the long-term outcomes with repair of this condition. METHODS: A retrospective study was conducted at 2 institutions. From 1984 to 2018, 33 patients with PA sling underwent repair. RESULTS: The median age at the time of surgery was 5.9 months (quartile 1–3: 2.5–12 months). Concomitant tracheal surgery was required in 21 patients (64%) where slide tracheoplasty was used in 11 patients (52%). There were no early deaths in patients who did not require tracheal surgery (n = 12). Operative mortality was 22% (2 of 9 patients) between 1984 and 1993, 11% (1 of 9 patients) between 1994 and 2003 and 6.7% (1 of 15 patients) between 2004 and 2018. The 15-year probability of survival for patients who had PA sling repair alone was 100%, and for patients who required PA sling and tracheal repair was 76 ± 10% (95% confidence interval 51–89%) (P = 0.08). The mean follow-up for survivors was 14 ± 9.8 years (3 months–33 years). All survivors were in the New York Heart Association functional class I/II at the last follow-up. Spirometry performed at a median age of 10.4 years after PA sling and tracheal surgery demonstrated obstructive lung defects with median forced expiratory volume in 1 s of 1.0 l (48% predicted), forced vital capacity of 1.5 l (74% predicted) and forced expiratory volume in 1 s/forced vital capacity of 0.69 (78% predicted). CONCLUSIONS: Early mortality after PA sling repair is determined by the need for tracheal surgery. Though late survival was excellent, and the majority of survivors remained asymptomatic, long-term respiratory assessment and follow-up is warranted for these patients.

1 July 2020 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
TFTyson A. Fricke
Tyson A. Fricke
DBDouglas Bell
Douglas Bell
MDMichael Daley
Michael Daley
YDYves D'UDekem
Yves D'UDekem
CBChristian P. Brizard
Christian P. Brizard
IKIgor E. Konstantinov
Igor E. Konstantinov

1 January 2017 in Seminars in Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
SPSudesh Prabhu
Sudesh Prabhu
JAJane E. Armes
Jane E. Armes
DBDouglas Bell
Douglas Bell
RJRobert Justo
Robert Justo
PVPrem Venugopal
Prem Venugopal
Nelson AlphonsoNelson Alphonso
Nelson Alphonso

7 August 2018 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Closed access
DBDouglas Bell
Douglas Bell
SPSudesh Prabhu
Sudesh Prabhu
KBKim Betts
Kim Betts
RJRobert Justo
Robert Justo
PVPrem Venugopal
Prem Venugopal
Nelson AlphonsoNelson Alphonso
Nelson Alphonso
This study aims to assess the performance of tissue-engineered bovine pericardium (CardioCel®) at 24 months and beyond when used for the repair of congenital heart defects. Between October 2012 and November 2014, CardioCel was implanted in 135 patients (140 procedures and 195 implants). Applications included the closure of septal defects (98, 50.3%), repair of pulmonary arteries (63, 32.3%), intra-atrial/intraventricular baffles (10, 5.1%), repair of systemic arteries (15, 7.7%), valve repair (5, 2.6%), repair of systemic veins (3, 1.5%) and Fontan operation (1, 0.5%). There were 19 (13.6%) procedures performed in neonates, 77 (55%) in infants and 44 (31.4%) in children older than 365 days. Eight patients (n = 135, 5.9%) required reintervention in 12 instances (n = 195, 6.2%, 6 catheters and 6 surgical). There was no echocardiographic or radiological evidence of calcification in any patient. Ten of the reinterventions (83%) occurred within the first 12 months. All the reinterventions occurred within 36 months. Freedom from reintervention at both 12 and 24 months was 95% [confidence interval (CI) 91-97] and at 36 months was 94% (CI 89-97). There was no statistical difference in freedom from reintervention when stratified by age or patch position. At 24 months and beyond the follow-up, the performance of CardioCel remains acceptable with good haemodynamic performance. There was no echocardiographic or radiological evidence of calcification in any patient. CardioCel performs comparably in systemic and pulmonary circulations.